The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Cancer biomarkers: knowing the present and predicting the future
Abstract
In recent years the discovery of cancer biomarkers has become a major focus of cancer research. The widespread use of prostate-specific antigen in prostate cancer screening has motivated researchers to identify suitable markers for screening different types of cancer. Biomarkers are also useful for diagnosis, monitoring disease progression, predicting disease recurrence and therapeutic treatment efficacy. With the advent of new and improved genomic and proteomic technologies such as DNA and tissue microarray, two-dimensional gel eletrophoresis, mass spectrometry and protein assays coupled with advanced bioinformatic tools, it is possible to develop biomarkers that are able to reliably and accurately predict outcomes during cancer management and treatment. In years to come, a serum or urine test for every phase of cancer may drive clinical decision making, supplementing or replacing currently existing invasive techniques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags
Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999) · Nature Biotechnology · doi:10.1038/13690 · Cited by 4,683 · cited 1×
“This technology has been used to identify and quantify expression of proteins from cells, tissues or other biological fluids [89].”
MethodSerial Analysis of Gene Expression
Velculescu, V. E., Zhang, L., Vogelstein, B., & Kinzler, K. W. (1995) · Science · doi:10.1126/science.270.5235.484 · Cited by 3,711
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Use of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
Light-Directed, Spatially Addressable Parallel Chemical Synthesis
Fodor, S. P. A., Read, J. L., Pirrung, M. C., Stryer, L., Lu, A. T., & Solas, D. (1991) · Science · doi:10.1126/science.1990438 · Cited by 2,696
Gold, P., & Freedman, S. O. (1965) · The Journal of Experimental Medicine · doi:10.1084/jem.121.3.439 · Cited by 2,310
High density synthetic oligonucleotide arrays
Lipshutz, R. J., Fodor, S. P. A., Gingeras, T. R., & Lockhart, D. J. (1999) · Nature Genetics · doi:10.1038/4447 · Cited by 2,205
Multiclass cancer diagnosis using tumor gene expression signatures
Ramaswamy, S., Tamayo, P., Rifkin, R., Mukherjee, S., Yeang, C.-H., Angelo, M., Ladd, C., Reich, M., Latulippe, E., Mesirov, J. P., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211566398 · Cited by 2,023
SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEM
Gold, P., & Freedman, S. O. (1965) · The Journal of Experimental Medicine · doi:10.1084/jem.122.3.467 · Cited by 1,879
Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., & Gasparini, G. (1992) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/84.24.1875 · Cited by 1,775
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686 · cited 2×
“Pepe and colleagues proposed a five-phase formal categorization that would guide the development of a biomarker [94].”
BackgroundRhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pandey, A., & Chinnaiyan, A. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401994101 · Cited by 1,019
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
Proteomic applications for the early detection of cancer
Wulfkuhle, J. D., Liotta, L. A., & Petricoin, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1043 · Cited by 907
Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy
D'Amico, A. V., Chen, M.-H., Roehl, K. A., & Catalona, W. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032975 · Cited by 740
Baggerly, K. A., Morris, J. S., & Coombes, K. R. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg484 · Cited by 621
Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical Endpoints
Torhorst, J., Bucher, C., Kononen, J., Haas, P., Zuber, M., Köchli, O. R., Mross, F., Dieterich, H., Moch, H., Mihatsch, M., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63075-1 · Cited by 566
Induction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1
Harkin, D. P., Bean, J. M., Miklos, D., Song, Y.-H., Truong, V. B., Englert, C., Christians, F. C., Ellisen, L. W., Maheswaran, S., Oliner, J. D., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80769-2 · Cited by 557
SERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMY
Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I., & Walsh, P. C. (1993) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00924-1 · Cited by 460
Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate Cancer
Barry, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441806 · Cited by 438
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
Khan, J. I., Simon, R., Bittner, M. L., Chen, Y., Leighton, S. B., Pohida, T. J., Smith, P. D., Jiang, Y. Y., Gooden, G. C., Trent, J. M., et al. (1998) · PubMed · Cited by 437
Role of osteopontin in tumour progression
Rittling, S. R., & Chambers, A. F. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601839 · Cited by 413
Moch, H., Schraml, P., Bubendorf, L., Mirlacher, M., Kononen, J., Gasser, T., Mihatsch, M. J., Kallioniemi, O. P., & Sauter, G. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65349-7 · Cited by 391
Zhou, G., Li, H., DeCamp, D., Chen, S., Shu, H., Gong, Y., Flaig, M., Gillespie, J. W., Hu, N., Taylor, P. R., et al. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m100015-mcp200 · Cited by 388
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.
Fedarko, N. S., Jain, A., Karadağ, A., Eman, M. R. V., & Fisher, L. W. (2001) · PubMed · Cited by 380
Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers
Halling, K. C., French, A. J., McDonnell, S. K., Burgart, L. J., Schaid, D. J., Peterson, B. J., Moon-Tasson, L., Mahoney, M. R., Sargent, D. J., O'Connell, M. J., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1295 · Cited by 375
PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCER
MOUL, J. W. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67511-8 · Cited by 350
Bubendorf, L., Kolmer, M., Kononen, J., Koivisto, P., Mousses, S., Chen, Y., Mahlamaki, E., Schraml, P., Moch, H., Willi, N., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.20.1758 · Cited by 350
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Harris, R., & Lohr, K. N. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-11-200212030-00014 · Cited by 348
Proteomic Patterns in Biological Fluids: Do They Represent the Future of Cancer Diagnostics?
Diamandis, E. P. (2003) · Clinical Chemistry · doi:10.1373/49.8.1272 · Cited by 324
Bartsch, G., Horninger, W., Klocker, H., Reissigl, A., Oberaigner, W., Schönitzer, D., Severi, G., Robertson, C., & Boyle, P. (2001) · Urology · doi:10.1016/s0090-4295(01)01264-x · Cited by 315
Jones, M. B., Krutzsch, H., Shu, H., Zhao, Y., Liotta, L. A., Kohn, E. C., & Petricoin, E. F. (2002) · PROTEOMICS · doi:10.1002/1615-9861(200201)2:1<76::aid-prot76>3.0.co;2-o · Cited by 290
Rhodes, D. R., Sanda, M. G., Otte, A. P., Chinnaiyan, A. M., & Rubin, M. A. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.661 · Cited by 271
The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer.
Ayala, G., Wang, D.-G., Wulf, G. M., Frolov, A., Li, R., Sowadski, J. M., Wheeler, T. M., Lu, K. P., & Bao, L. (2003) · PubMed · Cited by 250
Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer.
Bubb, V., Curtis, L. J., Cunningham, C., Dunlop, M. G., Carothers, A. D., Rg, M., White, S., Bird, C. C., & Wyllie, A. H. (1996) · PubMed · Cited by 246
Alevizos, I., Mahadevappa, M., Zhang, X., Ohyama, H., Kohno, Y., Posner, M., Gallagher, G. T., Varvares, M., Cohen, D., Kim, D., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204685 · Cited by 234
Everley, P. A., Krijgsveld, J., Zetter, B. R., & Gygi, S. P. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400021-mcp200 · Cited by 226
Self-citationMatrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma
Talvensaari-Mattila, A., P��kk�, P., H�yhty�, M., Blanco-Sequeiros, G., & Turpeenniemi-Hujanen, T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980915)83:6<1153::aid-cncr14>3.0.co;2-4 · Cited by 217
Kattan, M. W., Shariat, S. F., Andrews, B., Zhu, K., Canto, E., Matsumoto, K., Muramoto, M., Scardino, P. T., Ohori, M., Wheeler, T. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.037 · Cited by 208
Urokinase Plasminogen Activator System: A Multifunctional Role in Tumor Progression and Metastasis
Choong, P., & Nadesapillai, A. P. W. (2003) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo0000093845.72468.bd · Cited by 208
Wang, Y., Wu, M., Sham, J. S. T., Zhang, W., Wu, W., & Guan, X. (2002) · Cancer · doi:10.1002/cncr.10963 · Cited by 198
New approaches to proteomic analysis of breast cancer
Wulfkuhle, J. D., McLean, K. C., Paweletz, C. P., Sgroi, D. C., Trock, B. J., Steeg, P. S., & Petricoin III, E. F. (2001) · PROTEOMICS · doi:10.1002/1615-9861(200110)1:10<1205::aid-prot1205>3.0.co;2-x · Cited by 198
Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong, P., & Nadesapillai, A. P. W. (2003) · PubMed · doi:10.1097/01.blo.0000093845.72468.bd · Cited by 167
The Role of Osteopontin in Breast Cancer: Clinical and Experimental Studies
Tuck, A. B., & Chambers, A. F. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1014734930781 · Cited by 160
Kageyama, S., Isono, T., Iwaki, H., Wakabayashi, Y., Okada, Y., Kontani, K., Yoshimura, K., Terai, A., Arai, Y., & Yoshiki, T. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.027425 · Cited by 160
Thymosin β15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer
Bao, L., Loda, M. F., Janmey, P. A., Stewart, R., Anand‐Apte, B., & Zetter, B. R. (1996) · Nature Medicine · doi:10.1038/nm1296-1322 · Cited by 158
Self-citationURINE BASED MARKERS OF UROLOGICAL MALIGNANCY
Konety, B. R., & Getzenberg, R. H. (2001) · The Journal of Urology · doi:10.1097/00005392-200102000-00081 · Cited by 150
Prognostic significance of cathepsins B and L in primary human breast cancer.
Foekens, J. A., Kos, J., Peters, H. A., Krašovec, M., Look, M. P., Cimerman, N. G., Gelder, M. E. M., Henzen-Logmans, S. C., van Putten, W. L., & Klijn, J. G. M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1013 · Cited by 150
Clinical potential of proteomics in the diagnosis of ovarian cancer
Ardekani, A. M., Liotta, L. A., & Petricoin, E. F. (2002) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2.4.312 · Cited by 131
Proteomic Approaches to the Diagnosis, Treatment, and Monitoring of Cancer
Wulfkuhle, J. D., Paweletz, C. P., Steeg, P. S., Petricoin, E. F., & Liotta, L. A. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0081-0_7 · Cited by 126
Blackwell, K., Hurwitz, H. I., Liebérman, G., Novotny, W. F., Snyder, S. A., Dewhirst, M. W., & Greenberg, C. S. (2004) · Cancer · doi:10.1002/cncr.20336 · Cited by 126
Chaı̈b, H., Cockrell, E. K., Rubin, M. A., & Macoska, J. A. (2001) · Neoplasia · doi:10.1038/sj.neo.7900126 · Cited by 117
Type XXIII Collagen, a New Transmembrane Collagen Identified in Metastatic Tumor Cells
Banyard, J., Bao, L., & Zetter, B. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210616200 · Cited by 116
Self-citationHegde, P. S., Qi, R., Gaspard, R. M., Abernathy, K., Dharap, S. S., EARLE-HUGHES, J. A., Gay, C., Nwokekeh, N., Chen, T., Saeed, A., et al. (2001) · PubMed · Cited by 109
Jung, K., Elgeti, U., Lein, M., Brux, B., Sinha, P. K., Rudolph, B. D., Hauptmann, S., Schnorr, D., & Loening, S. A. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.1.55 · Cited by 97
Meehan, K. L., & Sadar, M. D. (2004) · PROTEOMICS · doi:10.1002/pmic.200300649 · Cited by 70
Grizzle, W. E., Adam, B.-L., Bigbee, W. L., Conrads, T. P., Carroll, C. A., Feng, Z., Izbicka, E., Jendoubi, M., Johnsey, D., Kagan, J., et al. (2004) · Disease Markers · doi:10.1155/2004/546293 · Cited by 65
Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian Cancer
Paju, A., Vartiainen, J., Haglund, C., Itkonen, O., von Boguslawski, K., Leminen, A., Wahlström, T., & Stenman, U. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0204-03 · Cited by 60
Laser Capture Microdissection and Advanced Molecular Analysis of Human Breast Cancer
Fuller, A. P., Palmer-Toy, D. E., Erlander, M. G., & Sgroi, D. C. (2003) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000010033.49464.0c · Cited by 60
Thymosin β15 expression in tumor cell lines with varying metastatic potential
Bao, L., Loda, M. F., & Zetter, B. R. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006540824969 · Cited by 51
Self-citationBorštnar, S., Vrhovec, I., Svetic, B., & Čufer, T. (2002) · Clinical Breast Cancer · doi:10.3816/cbc.2002.n.018 · Cited by 38
DNA array‐based method for detection of large rearrangements in the BRCA1 gene
Frolov, A., Prowse, A. H., Vanderveer, L., Bove, B. A., Wu, H., & Godwin, A. K. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10109 · Cited by 32
Prostate cancer: Detection, staging, and treatment of localized disease
Potter, S. R., & Partin, A. W. (1999) · Seminars in Roentgenology · doi:10.1016/s0037-198x(99)80005-4 · Cited by 8
Cited by
Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology
Bera, K., Schalper, K. A., Rimm, D. L., Velcheti, V., & Madabhushi, A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0252-y · Cited by 1,698
Recent advances in biosensor development for the detection of cancer biomarkers
Jayanthi, V. S. P. K. S. A., Das, A. B., & Saxena, U. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.12.014 · Cited by 565
Early Diagnosis of Breast Cancer
Wang, L. (2017) · Sensors · doi:10.3390/s17071572 · Cited by 549
Ali, E. S., Sharker, S. M., Islam, M. T., Khan, I. N., Shaw, S., Rahman, M. A., Uddin, S. J., Shill, M. C., Rehman, S., Das, N., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.011 · Cited by 267
Label-Free Plasmonic Biosensors for Point-of-Care Diagnostics: A Review
Soler, M., Huertas, C. S., & Lechuga, L. M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1554435 · Cited by 236
Metadata
- Authors
- Chatterjee, S. K., & Zetter, B. R.
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2005-02
- Volume
- 1
- Issue
- 1
- Pages
- 37-50
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W2052508124
- Cited by
- 269
- References
- 67
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.